Navigation Links
Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
Date:2/4/2008

inistered once every two weeks by a healthcare professional and avoids the need for patients to remember to take daily antipsychotic medications. "

In the study, 139 patients were randomized to receive either RLAI 25-50mg intramuscular injection (n=72), or placebo injections (n=67) adjunctive to standard treatment. Patients receiving RLAI plus standard treatment were eligible to enter the double blind phase of the trial if they met predefined criteria(a) for being stable the last four weeks of the 16-week open-label stabilization phase.

In the study, Frequently Relapsing Bipolar Disorder: Evidence for an Effective Treatment Using Adjunctive Risperidone Long-Acting Injectable, 67% of patients randomized received a 25 mg dose of RLAI, 29% received a 37.5 mg dose and 4% received a 50 mg dose, administered once every two weeks.

The primary efficacy endpoint in the double-blind phase of the trial was the time from randomization to relapse, where relapse was defined as the first occurrence of a mood episode as determined by an independent Relapse Monitoring Board (RMB).(b)

The results showed a significant difference in time to relapse (p=0.004), with a more than two-fold higher risk of relapse in the placebo group (47.8%) than the RLAI group (22.2%). In addition, scores on the Clinical Global Impression-Bipolar-Severity (CGI-BP-S) scale for overall bipolar disorder and the Clinical Global Impression-Bipolar-Change (CGI-BP-C) scale worsened significantly (p<0.05) in the placebo group compared with the RLAI group.

Treatment-emergent adverse effects (TEAEs) occurred more frequently in the group that received placebo and standard treatment (76.1%) than in the group that received RLAI and standard treatment (70.8%), as did serious adverse effects (placebo=19.4%; RLAI = 13.9%). The most common TEAEs (greater than 5%) in the double-blind phase were tremor (RLAI = 23.6%; placebo = 16.4%), insomnia (RLAI = 19.4%; placebo = 23.9%), muscle rigidity
'/>"/>

SOURCE Janssen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says
5. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
6. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
7. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
8. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
9. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
10. Study Examines Media Preferences of Life Scientists in Applied Markets
11. Triage study challenges notions of emergency medical response to disaster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... MA (PRWEB) , ... August 27, 2015 , ... Inc. ... United States, ranking iLab Solutions as number 1,361 in growth for the three years ... of the top 0.1% fastest-growing privately held organizations in the country. , “We ...
(Date:8/26/2015)... Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended June 30, ... Canadian dollars and presented under International Financial Reporting ... with respect to our Oral Amp B program, ... manufacturer," said Andrew Rae , President & ...
(Date:8/26/2015)... , Aug. 26, 2015 Intrexon Corporation ... announced today the closing of its previously announced public ... by the underwriters of their option to purchase an ... offering price of $41.00 per share.  The exercise of ... of common stock sold by Intrexon to 5,609,756 shares ...
(Date:8/26/2015)... Bruno, CA. (PRWEB) , ... August 26, 2015 , ... ... major conferences to develop new business relationships with local sponsors in southern California. The ... to facilitate their drug development processes and regulatory pathways., , ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... CLARA, Calif., Sept. 8 Cell Biosciences, Inc. and Alpha ... have entered into a definitive agreement providing for the acquisition ... or approximately $17.9 million in cash. This acquisition would significantly ... infrastructure and a broad protein analysis product portfolio. , ...
... NEW YORK, Sept. 8 /PRNewswire-Asia-FirstCall/ -- ... Company" or "AOBO"), a pharmaceutical,company dedicated to improving health ... of prescription and over the counter ("OTC"),products, today announced ... -- Morgan Stanley Healthcare Corporate Day, to ...
... Sept. 8, Palatin Technologies, Inc. (NYSE Amex: PTN ... ended June 30, 2009. For the year ended June 30, ... year ended June 30, 2008. Palatin,s net loss for the ... basic and diluted share, compared to a net loss of $14.4 ...
Cached Biology Technology:Cell Biosciences Signs Agreement to Acquire Alpha Innotech 2Cell Biosciences Signs Agreement to Acquire Alpha Innotech 3Cell Biosciences Signs Agreement to Acquire Alpha Innotech 4Cell Biosciences Signs Agreement to Acquire Alpha Innotech 5American Oriental Bioengineering Announces September Investor Conferences Participation 2Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 2Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 3Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 4Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 5Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 6Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 7
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... lower blood pressure (BP), and the diets can also be ... body weight, physical activity and alcohol intake play a role ... shown to be effective for preventing and managing hypertension. ... from 1900 to 2013 in which participants ate a vegetarian ...
... capture on video. Now researchers at Princeton University have achieved ... to break into and infect a cell. The technique they ... drugs via nanoparticles which are about the same size ... infection from occurring. The video reveals a virus-like particle ...
... or a busy airport where cold viruses and other germs ... as bees and butterflies can pick up fungal, bacterial or ... or as debilitating as influenza. But "almost nothing ... flowers," postdoctoral researcher Scott McArt and Professor Lynn Adler at ...
Cached Biology News:Now in 3-D: Video of virus-sized particle trying to enter cell 2Now in 3-D: Video of virus-sized particle trying to enter cell 3As hubs for bees and pollinators, flowers may be crucial in disease transmission 2
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
...
Bovine Serum...
Healthy animals 10-32 weeks of age, mixed gender and breed; collected on wet ice following USDA guidelines, using Alsevers solution at 1:2 dilution...
Biology Products: